Truist Financial Forecasts Strong Price Appreciation for Lantheus (NASDAQ:LNTH) Stock

Lantheus (NASDAQ:LNTH) had its price objective raised by investment analysts at Truist Financial from $80.00 to $82.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s price objective points to a potential upside of 25.55% from the company’s current price.

Several other research firms have also commented on LNTH. The Goldman Sachs Group set a $77.00 price objective on shares of Lantheus and gave the stock a “neutral” rating in a research note on Wednesday, October 8th. TD Cowen decreased their price objective on Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, September 15th. Mizuho raised their price objective on Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday. Weiss Ratings downgraded Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Finally, B. Riley decreased their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a research note on Tuesday, September 16th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and an average target price of $78.00.

Lantheus Stock Up 0.1%

Shares of LNTH traded up $0.07 during trading hours on Thursday, hitting $65.31. The company had a trading volume of 43,852 shares, compared to its average volume of 1,243,947. Lantheus has a one year low of $47.25 and a one year high of $111.29. The company’s fifty day moving average price is $57.35 and its two-hundred day moving average price is $62.90. The company has a market capitalization of $4.33 billion, a PE ratio of 27.50 and a beta of -0.10. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $92.51 million for the quarter. Lantheus had a return on equity of 30.88% and a net margin of 10.99%. As a group, equities analysts forecast that Lantheus will post 6.01 earnings per share for the current fiscal year.

Institutional Trading of Lantheus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LNTH. Hantz Financial Services Inc. increased its holdings in Lantheus by 412.5% in the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 396 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in shares of Lantheus during the 2nd quarter valued at about $26,000. First Horizon Corp purchased a new position in shares of Lantheus in the 3rd quarter valued at about $26,000. Osterweis Capital Management Inc. acquired a new position in Lantheus in the 2nd quarter worth about $36,000. Finally, Quarry LP grew its holdings in Lantheus by 2,350.0% in the first quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock valued at $48,000 after purchasing an additional 470 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.